Periodic Reporting for period 1 - Pulmonary Fibrosis (Glycomic and Genomic Repercussion of Nebulisable Gal-3 Inhibitory Medical Device Treatment in Pulmonary Fibrosis)

Idiopathic pulmonary fibrosis (IPF) is the most common of idiopathic interstitial pneumonia with an increasing prevalence due to aged population, lifestyle and environmental exposure [1]. Today there is no cure for IPF, there is only two approved treatments that slow down...